SUPPLEMENTAL DATA

A synthetic peptide designed to neutralize lipopolysaccharides attenuates metaflammation and diet-induced metabolic derangements in mice

Shireen Mohammad1, Sura Al Zoubi1,2, Debora Collotta3, Nadine Krieg4,5, Bianka Wissuwa4,5, Gustavo Ferreira Alves3, Giuseppe Danilo Norata6,7,8, Andrea Baragetti6,7, Alberico Luigi Catapano6,7,8, Egle Solito1,9, Elisabeth Zechendorf10, Tobias Schürholz10, Wilmar Correa11, Klaus Brandenburg12, Sina M. Coldewey4,5, Massimo Collino3, Muhammad M. Yaqoob1, Lukas Martin1,10#, Christoph Thiemermann1*#

1William Harvey Research Institute, Bart’s and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
2Department of Basic Medical Sciences, School of Medicine, Al-Balqa Applied University, As-Salt, Jordan
3Department of Drug Science and Technology, University of Turin, Turin, Italy
4Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany
5Septomics Research Center, Jena University Hospital, Jena, Germany
6Department of Pharmacological and Biomolecular Sciences, University of Milan, 20133, Italy
7IRCCS Multimedica, 20099 Sesto San Giovanni, Italy
8S.I.S.A. Centre for the Study of Atherosclerosis, Bassini Hospital, 20092 Cinisello Balsamo, Milan, Italy
9Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli “Federico II”, Napoli, Italy
10Department of Intensive Care and Intermediate Care, University Hospital RWTH Aachen, Aachen, Germany
11Forschungszentrum Borstel, Department of Biophysics, D-23845 Borstel, Germany
12Brandenburg Antiinfektiva GmbH, c/o Forschungszentrum Borstel

#both authors contributed equally to this work

*Corresponding authors:
Shireen Mohammad s.mohammad@qmul.ac.uk Queen Mary University London
Prof Chris Thiemermann, MD PhD FMedSci c.thiemermann@qmul.ac.uk The William Harvey Research Institute
Centre for Translational Medicine & Therapeutics
Charterhouse Square
London EC1M 6BQ, UK
Phone: +44 (0) 20 78822107

Conflict of interest statement: The authors have declared that no conflict of interest exists.
Supplemental Figures

Figure S1: Effect of peptide 19-2.5 administration on food and caloric intake in HFD-fed mice. Weekly data was collected to report (A) calories intake (Kcal/mouse/day) and (B) food intake (grams/mouse/day). Data was analyzed by one-way ANOVA, with Bonferroni post-hoc test. Data are expressed as mean ± SEM; n = 20 per group.
Figure S2: Effect of peptide 19-2.5 administration on OGTT at week 6 in HFD-fed mice. Oral glucose tolerance (OGTT) was assessed over 120 min, after receiving the oral dose of glucose at week 6 (mg/dl). Data are expressed as mean ± SEM; n = 20 per group. **P < 0.01 and ****P < 0.0001 vs. HFD + Veh.
Figure S3: Z score heatmap of primary metabolites. Heatmap of all primary metabolites that are significantly different for any of the tested groupwise comparisons. Z scores are shown for all samples. Each column represents an individual sample and each row defines an analyte. Samples from Chow (n=8), HFD+Veh (n=13) and HFD+Pep2.5 (n=11) were arranged from left to right. Analytes were hierarchically clustered using Ward's minimum variance method\textsuperscript{1} and an euclidian distance between z scores. Dendrograms provide information about distances between clusters.
Figure S4. Z score heatmap of phospholipids. Heatmap of all phospholipids that are significantly different for any of the tested groupwise comparisons. Z scores are shown for all samples. Each column represents an individual sample and each row defines an analyte. Samples from Chow (n=8), HFD+Veh (n=13) and HFD+Pep2.5 (n=11) were arranged from left to right. Analytes were hierarchically clustered using Ward’s minimum variance method and an euclidian distance between z scores. Dendrograms provide information about distances between clusters. LPC: Lysophosphatidylcholine, PC: phosphatidylcholine, LPE: lysophosphatidylethanolamin, PE: phosphatidylethanolamine, LPI: lysophosphatidylinositol, PI: phosphatidylinositol, LPS: lysophosphatidylserine, SM: sphingomyeline.
Figure S5: Z score heatmap of lipid mediators. Heatmap of all lipid mediators that are significantly different for any of the tested groupwise comparisons. Z scores are shown for all samples. Each column represents an individual sample and each row defines an analyte. Samples from Chow (n=8), HFD+Veh (n=13) and HFD+Pep2.5 (n=11) were arranged from left to right. Analytes were hierarchically clustered using Ward's minimum variance method and an euclidian distance between z scores. Dendrograms provide information about distances between clusters. EPA: eicosapentaenoic acid, DHA: docosahexaenoic acid, AA: arachidonic acid, AEA: arachidonoylethanolamide, OEA: oleoylethanolamine, HETE: hydroxyeicosatetraenoic acid.
Figure S6: Log2 fold change heatmap of phospholipids. Heatmap of all detected phospholipids. Log2 fold changes and * P< 0.05 are shown for all tested groupwise comparisons: HFD+Veh (n = 13) vs. Chow (n = 8), HFD+Pep2.5 (n = 11) vs. Chow and HFD+Pep2.5 vs. HFD+Veh. Each column represents a groupwise comparison and each row defines an analyte. Analytes were hierarchically clustered using Ward's minimum variance method and an euclidian distance between log2 fold changes. Dendrograms provide information about distances between clusters. Black frames show analytes with significant differences between the Chow and HFD+Veh group as well as between the HFD+Veh and HFD+Pep2.5 group. LPC: lysophosphatidylcholine, PC: phosphatidylcholine, LPE: lysophosphatidylethanolamine, PE: phosphatidylethanolamine, LPI: lysophosphatidylinositol, PI: phosphatidylinositol, LPS: lysophosphatidylserine, SM: sphingomyelne.
Figure S7: Log2 fold change heatmap of lipid mediators. Heatmap of all detected lipid mediators. Log2 fold changes and * P< 0.05 are shown for all tested groupwise comparisons: HFD+Veh (n = 13) vs. Chow (n = 8), HFD+Pep-2.5 (n = 11) vs. Chow and HFD+Pep2.5 vs. HFD+Veh. Each column represents a groupwise comparison and each row defines an analyte. Analytes were hierarchically clustered using Ward's minimum variance method [1] and an euclidian distance between log2 fold changes. Dendrograms provide information about distances between clusters. Black frames show analytes with significant differences between the Chow and HF+Veh group as well as between the HFD+Veh and HFD+Pep2.5 group. EPA: eicosapentaenoic acid, Lyso-PAF: lyso-platelet activating factor, DHA: docosahexaenoic acid, DiHOME: dihydroxy-octadecenoic acid, HDoHE: hydroxy-docosahexaenoic acid, HETE: hydroxyeicosatetraenoic acid, AA: arachidonic acid, AEA: arachidonoyl ethanolamide, OEA: oleoylethanolamine, HODE: Hydroxyoctadecadienoic acid, EpOME: epoxyoctamonoenoic acid.
Figure S8: Volcano plots of phospholipids. Volcano plots of all tested groupwise comparisons of phospholipids showing log2 fold changes and adjusted P-values. (A) HFD+Veh (n = 13) vs. Chow (n = 8), (B) HFD+Pep2.5 (n = 11) vs. Chow and (C) HFD+Pep2.5 vs. HFD+Veh. Significantly different analytes are colored according to their lipid classes. Analytes with absolute log2 fold changes above 1 (grey dashed lines) are labeled. Grey dots represent analytes that were not significantly different for the respective groupwise comparison. LPC: lysophosphatidylcholine, PC: phosphatidylcholine, LPE: lysophosphatidylethanolamine, PE: phosphatidylethanolamine, LPI: lysophosphatidylinositol, PI: phosphatidylinositol, LPS: lysophosphatidylserine, SM: sphingomyeline.
Figure S9: Volcano plots of lipid mediators. Volcano plots of all tested groupwise comparisons of lipid mediators showing log2 fold changes and adjusted P-values. (A) HFD+Veh (n=13) vs. Chow (n=8), (B) HFD+Pep2.5 (n=11) vs. Chow and (C) HFD+Pep2.5 vs. HFD+Veh. Significantly different analytes are depicted as black circles. Grey dots represent analytes that were not significantly different for the respective comparison. Grey dashed lines indicate absolute log 2fold change of one. EPA: eicosapentaenoic acid, DHA: docosahexaenoic acid, AA: arachidonic acid, AEA: arachidonoylethanolamide, OEA: oleoylethanolamine, HETE: hydroxyeicosatetraenoic acid.
Table S1. Patient sample from healthy and T2DM patients.

|                                | Healthy (n=10) | T2DM patients (n=12) |
|--------------------------------|---------------|----------------------|
| Age (years)                    | 63 (61-68)    | 65 (54-74) (*)       |
| Gender (n, men, %)             | 5 (50)        | 9 (75) (*)           |
| Current smoking habit (n,%)    | 5 (50)        | 7 (58)               |
| Current use of alcoholic drinks (n,%) | 4 (40)    | 7 (58)               |
| BMI (Kg/m2)                    | 26.48 (3.78)  | 30.11 (7.50) (*)     |
| waist circumference (cm)       | 90.67 (8.28)  | 101.77 (16.32) (*)   |
| systolic blood pressure (mmHg) | 138.60 (12.50)| 131.50 (17.00)       |
| diastolic blood pressure (mmHg)| 83.60 (4.75)  | 81.50 (13.75)        |
| anti-hypertensives (n,%)       | 6 (60)        | 10 (83) (*)          |
| glucose (mg/dl)                | 99.0 (9.6)    | 153.3 (76.5) (*)     |
| oral glucose lowering drugs (n,%) | 0 (0)       | 9 (75) (*)           |
| insulin analogues (n,%)        | 0 (0)         | 4 (33) (*)           |
| total cholesterol (mg/dl)      | 244.60 (31.0) | 196.16 (40.40) (*)   |
| HDL-C (mg/dl)                  | 54.70 (5.76)  | 44.66 (11.85) (*)    |
| Triglycerides (mg/dl)          | 110.00 (70.00-130.00) | 200.00 (95.00-250.75) (*) |
| LDL-C (mg/dl)                  | 167.80 (24.60) | 114.58 (38.40) (*)   |
| Lipid lowering therapies (n,%) | 3 (30)        | 7 (58)               |
| creatinine (mg/dl)             | 0.81 (0.78-0.96) | 1.66 (0.70-2.12) (*) |
| Glomerular Filtration Rate (Cockroft-Gault formula, ml/min/1.73 m2) | 79.56 (18.15) | 47.57 (27.43-80.52) (*) |
| Alanine Aminotransferase (ALT) (UI/ml) | 25 (22-28) | 20 (15-35) |
| Aspartate Aminotransferase (AST) (UI/ml) | 24 (19-27) | 20 (16-23) |
| Gamma-glutamyl Transpeptidase (GGT) (UI/ml) | 21 (18-37) | 21 (16-33) |
| C-Reactive Protein (mg/L)      | 0.18 (0.06-0.32) | 0.21 (0.07-0.43) (*) |

*P<0.05 data are presented either as mean (standard error) or median (inter-quartile range) based on their distribution (Shapiro-Wilk test for normality)
**Table S2. HPLC programs.** Solvent A: of 0.1% formic acid in water, solvent B: 0.1% formic acid in acetonitrile, solvent C: methanol, solvent D: 2-propanol. The column oven temperature was set to 50 °C.

| time [min] | flow [mL/min] | solvent A concentration [%] | solvent B concentration [%] | solvent C concentration [%] | solvent D concentration [%] | solvent B and C curve* |
|------------|---------------|-----------------------------|----------------------------|-----------------------------|----------------------------|------------------------|
|            |               |                             |                            |                             |                            |                        |
| primary metabolites |       |                             |                            |                             |                            |                        |
| 0.01       | 0.25          | 100                         |                             |                             |                            |                        |
| 2.00       | 0.25          | 100                         |                             |                             |                            |                        |
| 5.00       | 0.25          | 75                          |                             |                             |                            |                        |
| 11.00      | 0.25          | 65                          |                             |                             |                            |                        |
| 15.00      | 0.25          | 5                           |                             |                             |                            |                        |
| 20.00      | 0.25          | 5                           |                             |                             |                            |                        |
| 20.01      | 0.25          | 100                         |                             |                             |                            |                        |
| 25.00      | stop          |                             |                             |                             |                            |                        |
| lipid mediators |       |                             |                            |                             |                            |                        |
| 0          | 0.2           | 90                          | 10                          |                             |                            |                        |
| 10.0       | 0.2           | 75                          | 25                          |                             |                            |                        |
| 20.0       | 0.2           | 65                          | 35                          |                             |                            |                        |
| 40.0       | 0.2           | 25                          | 75                          |                             |                            |                        |
| 40.2       | 0.2           | 5                           | 95                          |                             |                            |                        |
| 50.0       | 0.2           | 5                           | 90                          |                             |                            |                        |
| 50.2       | 0.2           | 90                          | 10                          |                             |                            |                        |
| 59.0       | Stop          |                             |                             |                             |                            |                        |
| phospholipids |       |                             |                             |                             |                            |                        |
|     |     |     |     |     |
|-----|-----|-----|-----|-----|
| 0.0 | 0.15| 80  | 10  | 10  |
| 2.0 | 0.15| 80  | 10  | 10  |
| 4.0 | 0.15| 60  | 20  | 20  | -3 |
| 50.0| 0.15| 7.6 | 46.2| 46.2|
| 52.0| 0.15| 0   | 50  | 50  |
| 70.0| 0.15| 0   | 50  | 50  |
| 70.2| 0.15| 80  | 10  | 10  |
| 80.0| stop|     |     |     |

sphingosine-1-phosphate and sphingosine

|     |     |     |     |     |
|-----|-----|-----|-----|-----|
| 0   | 0.4 | 90  | 10  |     |
| 0.01| 0.4 | 0   | 100 |     |
| 3.00| 0.4 | 0   | 100 |     |
| 5.00| 0.8 | 0   | 100 |     |
| 7.00| 0.8 | 0   | 100 |     |
| 7.01| 0.8 | 90  | 10  |     |
| 7.80| 0.8 | 90  | 10  |     |
| 8.30| 0.3 | 90  | 10  |     |
| 9.50| 0.3 | 90  | 10  |     |
| 9.51| Stop|     |     |     |

*sets the gradient curve of the solvent (-10 to 10)
Table S3: Mass spectrometer (LCMS 8050) settings

| Source conditions                          | Parameters                  |
|-------------------------------------------|-----------------------------|
| nebulizing gas flow rate                  | 3.0 L/min                   |
| heating gas flow rate                     | 10.0 L/min                  |
| drying gas flow rate                      | 10.0 L/min                  |
| collision-induced dissociation gas pressure| 230 kPa                     |
| interface temperature                     | 300 °C                      |
| desolvation line temperature              | 250 °C                      |
| block heater temperature                  | 400 °C                      |
| ionization mode                           | electrospray ionisation (ESI)|
Table S4: Mass transitions for identified significantly changed primary metabolites. The target ion shows the multiple reaction monitoring (MRM) transitions, the ionization polarity (IP) shows the ionization mode of the electrospray ionization (ESI) source and the internal standard (IS) column assigns the number of the internal standard to the compounds with which they were evaluated. The internal standard is marked in bold letters. Injection volume of 20 µl sample.

| no. | compound                                      | target ion     | IP | IS |
|-----|-----------------------------------------------|----------------|----|----|
| 1   | 4-hydroxyproline                              | 132.10>86.05   | +  | 1  |
| 2   | acetylcarnitine                               | 204.10>85.05   | +  | 1  |
| 3   | adenosine monophosphate                       | 348.00>136.05  | +  | 1  |
| 4   | alanine                                       | 89.90>89.90    | +  | 1  |
| 5   | arginine                                      | 175.10>70.10   | +  | 1  |
| 6   | asparagine                                    | 133.10>87.15   | +  | 1  |
| 7   | aspartic acid                                 | 134.00>74.05   | +  | 1  |
| 8   | bilirubin                                     | 583.30>285.25  | -  | 1  |
| 9   | carnitine                                     | 162.10>103.05  | +  | 1  |
| 10  | choline                                       | 104.10>60.05   | +  | 1  |
| 11  | citric acid                                   | 191.20>111.10  | -  | 1  |
| 12  | citrulline                                    | 176.10>70.05   | +  | 1  |
| 13  | creatine                                      | 132.10>44.05   | +  | 1  |
| 14  | creatinine                                    | 114.10>44.05   | +  | 1  |
| 15  | cystathionine                                 | 223.00>88.05   | +  | 1  |
| 16  | cystine                                       | 241.00>151.95  | +  | 1  |
| 17  | cytidine                                      | 244.10>112.05  | +  | 1  |
| 18  | cytidine monophosphate                        | 324.00>112.05  | +  | 1  |
| 19  | dimethylarginine (symmetric/asymmetric)       | 203.10>70.15   | +  | 1  |
| 20  | dimethylglycine                               | 104.10>58.05   | +  | 1  |
| 21  | glutamic acid                                 | 147.90>84.10   | +  | 1  |
|   | Compound                      | Mass Transition | Polarity | IS |
|---|-------------------------------|-----------------|----------|----|
| 22| glutamine                     | 147.10>84.15    | + 1      |    |
| 23| glycine                       | 75.90>30.15     | + 1      |    |
| 24| guanosine                     | 284.00>152.00   | + 1      |    |
| 25| histidine                     | 155.90>110.10   | + 1      |    |
| 26| hypoxanthine                  | 137.00>55.05    | + 1      |    |
| 27| inosine                       | 269.10>137.05   | + 1      |    |
| 28| isocitric acid                | 191.20>111.10   | - 1      |    |
| 29| isoleucine                    | 132.10>69.15    | + 1      |    |
| 30| kynurenine                    | 209.10>192.05   | + 1      |    |
| 31| leucine                       | 132.10>30.05    | + 1      |    |
| 32| lysine                        | 147.10>84.10    | + 1      |    |
| 33| methionine                    | 149.90>56.10    | + 1      |    |
| 34| methionine sulfoxide          | 166.00>74.10    | + 1      |    |
| 35| niacinamide                   | 123.10>80.05    | + 1      |    |
| 36| norepinephrine                | 170.10>152.15   | + 1      |    |
| 37| ornithine                     | 133.10>70.10    | + 1      |    |
| 38| phenylalanine                 | 166.10>120.10   | + 1      |    |
| 39| proline                       | 116.10>70.15    | + 1      |    |
| 40| serine                        | 105.90>60.10    | + 1      |    |
| 41| serotonin                     | 177.10>160.10   | + 1      |    |
| 42| threonine                     | 120.10>74.15    | + 1      |    |
| 43| tryptophan                    | 205.10>188.15   | + 1      |    |
| 44| tyrosine                      | 182.10>136.10   | + 1      |    |
| 45| uracil                        | 113.00>70.00    | + 1      |    |
| 46| uric acid                     | 167.10>123.95   | - 1      |    |
| 47| uridine                       | 245.00>113.05   | + 1      |    |
| 48| valine                        | 118.10>72.15    | + 1      |    |
| 49| 2-morpholinoethanesulfonic acid (IS) | 194.00>80.15 | - 1      |    |

**Table S5: Mass transitions for identified significantly changed phospholipids.**

The target ion shows the multiple reaction monitoring (MRM) transitions, the ionization polarity (IP) shows the ionization mode of the ESI source and the internal standard (IS) column assigns the number of the internal standard to the lipid species with which they were evaluated. The internal standard is marked in bold letters. (LPC: lysophosphatidylcholine, PC: phosphatidylcholine, LPE: lysophosphatidylethanolamine, PE: phosphatidylethanolamine, LPG: lysophosphatidylglycerol, PG: phosphatidylglycerol, LPI: lysophosphatidylinositol, PI: phosphatidylinsitol, LPS: lysophosphatidylserine, PS: phosphatidylserine, SM: sphingomyelin)
| no. | lipid species   | target ion      | IP  | IS |
|-----|----------------|-----------------|-----|----|
| 1   | LPC(14:0)      | 468.3>184.10    | +   | 1  |
| 2   | LPC(16:0)*     | 496.4>184.10    | +   | 1  |
| 3   | LPC(16:1)      | 494.3>184.10    | +   | 1  |
| 4   | LPC(18:0)*     | 524.4>184.10    | +   | 1  |
| 5   | LPC(18:1)*     | 522.4>184.10    | +   | 1  |
| 6   | LPC(18:2)*     | 520.4>184.10    | +   | 1  |
| 7   | LPC(18:3)      | 518.3>184.10    | +   | 1  |
| 8   | LPC(20:0)      | 552.4>184.10    | +   | 1  |
| 9   | LPC(20:1)      | 550.4>184.10    | +   | 1  |
| 10  | LPC(20:2)      | 548.4>184.10    | +   | 1  |
| 11  | LPC(20:3)      | 546.4>184.10    | +   | 1  |
| 12  | LPC(20:4)      | 544.4>184.10    | +   | 1  |
| 13  | LPC(20:5)      | 542.3>184.10    | +   | 1  |
| 14  | LPC(22:0)      | 580.5>184.10    | +   | 1  |
| 15  | LPC(22:1)      | 578.4>184.10    | +   | 1  |
| 16  | LPC(22:6)      | 568.4>184.10    | +   | 1  |
| 17  | PC(28:1)       | 676.5>184.10    | +   | 2  |
| 18  | PC(30:0)       | 706.6>184.10    | +   | 2  |
| 19  | PC(30:1)       | 704.5>184.10    | +   | 2  |
| 20  | PC(30:2)       | 702.5>184.10    | +   | 2  |
| 21  | PC(32:0)       | 734.6>184.10    | +   | 2  |
| 22  | PC(32:1)       | 732.6>184.10    | +   | 2  |
| 23  | PC(32:2)       | 730.6>184.10    | +   | 2  |
| 24  | PC(32:3)       | 728.5>184.10    | +   | 2  |
| 25  | PC(34:1)*      | 760.6>184.10    | +   | 2  |
| 26  | PC(34:2)*      | 758.6>184.10    | +   | 2  |
| 27  | PC(34:3)       | 756.6>184.10    | +   | 2  |
| 28  | PC(34:4)       | 754.6>184.10    | +   | 2  |
| 29  | PC(36:0)       | 790.7>184.10    | +   | 2  |
| 30  | PC(36:1)*      | 788.6>184.10    | +   | 2  |
| 31  | PC(36:2)*      | 786.6>184.10    | +   | 2  |
|   | PC       |       |       |
|---|----------|-------|-------|
| 32| PC(36:3)*| 784.6 | >184.10 |
| 33| PC(36:4)*| 782.6 | >184.10 |
| 34| PC(36:5)*| 780.6 | >184.10 |
| 35| PC(36:6) | 778.6 | >184.10 |
| 36| PC(36:7) | 776.5 | >184.10 |
| 37| PC(38:0) | 818.7 | >184.10 |
| 38| PC(38:1) | 816.7 | >184.10 |
| 39| PC(38:2) | 814.7 | >184.10 |
| 40| PC(38:3)*| 812.6 | >184.10 |
| 41| PC(38:4)*| 810.6 | >184.10 |
| 42| PC(38:5)*| 808.6 | >184.10 |
| 43| PC(38:6)*| 806.6 | >184.10 |
| 44| PC(38:7)*| 804.6 | >184.10 |
| 45| PC(40:0) | 846.7 | >184.10 |
| 46| PC(40:1) | 844.7 | >184.10 |
| 47| PC(40:2) | 842.7 | >184.10 |
| 48| PC(40:3) | 840.7 | >184.10 |
| 49| PC(40:4) | 838.7 | >184.10 |
| 50| PC(40:5) | 836.6 | >184.10 |
| 51| PC(40:6)*| 834.6 | >184.10 |
| 52| PC(40:7)*| 832.6 | >184.10 |
| 53| PC(40:8) | 830.6 | >184.10 |
| 54| PC(42:1) | 872.7 | >184.10 |
| 55| PC(42:2) | 870.7 | >184.10 |
| 56| PC(42:3) | 868.7 | >184.10 |
| 57| PC(42:4) | 866.7 | >184.10 |
| 58| PC(42:5) | 864.7 | >184.10 |
| 59| PC(42:6) | 862.7 | >184.10 |
| 60| PC(42:7) | 860.6 | >184.10 |
| 61| PC(42:8) | 858.6 | >184.10 |
| 62| PC(42:9) | 856.6 | >184.10 |
| 63| PC(42:10)| 854.6 | >184.10 |
|    |                  |       |       |
|----|------------------|-------|-------|
| 64 | PC(44:0)         | 902.8 | 184.10|
| 65 | PC(44:6)         | 890.7 | 184.10|
| 66 | PC(44:7)         | 888.7 | 184.10|
| 67 | PC(44:12)        | 878.6 | 184.10|
| 68 | LPE(14:0)        | 426.3 | 285.25|
| 69 | LPE(16:0)        | 454.3 | 313.25|
| 70 | LPE(16:1)        | 452.3 | 311.25|
| 71 | LPE(18:0)        | 482.3 | 341.30|
| 72 | LPE(18:1)        | 480.3 | 339.30|
| 73 | LPE(18:2)        | 478.3 | 337.25|
| 74 | LPE(18:3)        | 476.3 | 335.25|
| 75 | LPE(20:0)        | 510.4 | 369.35|
| 76 | LPE(20:1)        | 508.4 | 367.30|
| 77 | LPE(20:2)        | 506.3 | 365.30|
| 78 | LPE(20:3)        | 504.3 | 363.30|
| 79 | LPE(20:4)        | 502.3 | 361.25|
| 80 | LPE(20:5)        | 500.3 | 359.25|
| 81 | LPE(22:6)        | 526.3 | 385.25|
| 82 | PE(30:1)         | 662.5 | 521.45|
| 83 | PE(30:2)         | 660.5 | 519.45|
| 84 | PE(34:0)         | 720.6 | 579.55|
| 85 | PE(34:1)         | 718.6 | 577.50|
| 86 | PE(34:2)         | 716.5 | 575.50|
| 87 | PE(34:3)         | 714.5 | 573.50|
| 88 | PE(36:0)         | 748.6 | 607.55|
| 89 | PE(36:1)         | 746.6 | 605.55|
| 90 | PE(36:2)         | 744.6 | 603.55|
| 91 | PE(36:3)         | 742.6 | 601.50|
| 92 | PE(36:4)         | 740.5 | 599.50|
| 93 | PE(36:5)         | 738.5 | 597.50|
| 94 | PE(36:6)         | 736.5 | 595.45|
| 95 | PE(38:0)         | 776.6 | 635.60|
|   |   |   |   |   |
|---|---|---|---|---|
| 96 | PE(38:1) | 774.6>633.60 + 2 |
| 97 | PE(38:2) | 772.6>631.55 + 2 |
| 98 | PE(38:3) | 770.6>629.55 + 2 |
| 99 | PE(38:4) | 768.6>627.55 + 2 |
| 100 | PE(38:5) | 766.6>625.50 + 2 |
| 101 | PE(38:6) | 764.5>623.50 + 2 |
| 102 | PE(38:7) | 762.5>621.50 + 2 |
| 103 | PE(40:0) | 804.7>663.65 + 2 |
| 104 | PE(40:2) | 800.6>659.60 + 2 |
| 105 | PE(40:3) | 798.6>657.60 + 2 |
| 106 | PE(40:4) | 796.6>655.55 + 2 |
| 107 | PE(40:5) | 794.6>653.55 + 2 |
| 108 | PE(40:6) | 792.6>651.55 + 2 |
| 109 | PE(40:7) | 790.6>649.50 + 2 |
| 110 | PE(40:8) | 788.5>647.50 + 2 |
| 111 | PE(40:9) | 786.5>645.50 + 2 |
| 112 | PE(42:0) | 832.7>691.65 + 2 |
| 113 | PE(42:1) | 830.7>689.65 + 2 |
| 114 | PE(42:2) | 828.7>687.65 + 2 |
| 115 | PE(42:3) | 826.7>685.60 + 2 |
| 116 | PE(42:10) | 812.5>671.50 + 2 |
| 117 | PE(44:0) | 860.7>719.70 + 2 |
| 118 | PE(44:12) | 836.5>695.50 + 2 |
| 119 | LPG(14:1) | 455.3>283.15 + 2 |
| 120 | LPI(16:0) | 571.3>241.00 - 2 |
| 121 | LPI(18:0) | 599.3>241.00 - 2 |
| 122 | LPI(18:1) | 597.3>241.00 - 2 |
| 123 | LPI(18:2) | 595.3>241.00 - 2 |
| 124 | LPI(20:4) | 619.3>241.00 - 2 |
| 125 | LPI(22:6) | 643.3>241.00 - 2 |
| 126 | PI(34:0) | 837.6>241.00 - 2 |
| 127 | PI(38:6) | 881.5>241.00 - 2 |
|   | Compound           | Retention Time |    |     |
|---|--------------------|----------------|----|-----|
| 128 | LPS(16:0)         | 498.3-313.25   | +  | 2   |
| 129 | LPS(18:0)         | 526.3-341.30   | +  | 2   |
| 130 | LPS(18:1)         | 524.3-339.30   | +  | 2   |
| 131 | LPS(18:2)         | 522.3-337.25   | +  | 2   |
| 132 | LPS(20:4)         | 546.3-361.25   | +  | 2   |
| 133 | LPS(22:6)         | 570.3-385.25   | +  | 2   |
| 134 | SM(32:1)          | 675.6-184.10   | +  | 2   |
| 135 | SM(32:2)          | 673.6-184.10   | +  | 2   |
| 136 | SM(34:1)          | 703.6-184.10   | +  | 2   |
| 137 | SM(34:2)          | 701.6-184.10   | +  | 2   |
| 138 | SM(36:2)          | 729.6-184.10   | +  | 2   |
| 139 | SM(36:3)          | 727.6-184.10   | +  | 2   |
| 140 | SM(36:4)          | 725.6-184.10   | +  | 2   |
| 141 | SM(38:1)          | 759.7-184.10   | +  | 2   |
| 142 | SM(38:2)          | 757.6-184.10   | +  | 2   |
| 143 | SM(38:3)          | 755.6-184.10   | +  | 2   |
| 144 | SM(40:1)          | 787.7-184.10   | +  | 2   |
| 145 | SM(40:2)          | 785.7-184.10   | +  | 2   |
| 146 | SM(40:7)          | 775.6-184.10   | +  | 2   |
| 147 | sphingosine (17:0) IS | 286.3-268.40   | +  | 1   |
| 148 | LPC(17:0) IS      | 510.4-184.30   | +  | 2   |

*1 µl sample injection volume
Table S6: Mass transitions for identified significantly changed lipid mediators.
The target ion shows the multiple reaction monitoring (MRM) transitions, the ionization polarity (IP) shows the ionization mode of the ESI source and the internal standard (IS) column assigns the number of the internal standard to the lipid mediators with which they were evaluated. The internal standard is marked in bold letters.

| no | lipid mediator | target ion | IP | IS |
|----|----------------|------------|----|----|
| 1  | 12,13-DiHOME   | 12,13-dihydroxy-octadecenoic acid | 313,2>183,1 | - 1 |
| 2  | 9,10-DiHOME    | 9,10-dihydroxy-octadecenoic acid | 313,2>201,2 | - 1 |
| no. | compound                | target ion        | IP | IS  |
|-----|-------------------------|-------------------|----|-----|
| 3   | 19-HETE                 | 19-hydroxyeicosatetraenoic acid | 319,2>275,2 | -  | 1   |
| 5   | Lyso-PAF                | lyso-platelet activating factor | 482,3>184,1 | -  | 1   |
| 6   | 13-HODE                 | 13-hydroxyoctadecadienoic acid | 295,2>195,1 | -  | 1   |
| 7   | 9-HODE                  | 9-hydroxyoctadecadienoic acid | 295,2>171,1 | -  | 1   |
| 8   | 16-HDoHE                | 16-hydroxy-docosahexaenoic acid | 343,2>233,2 | -  | 1   |
| 9   | 11-HETE                 | 11-hydroxyeicosatetraenoic acid | 319,2>167,1 | -  | 1   |
| 10  | 10-HDoHE                | 10-hydroxy-docosahexaenoic acid | 343,2>153,1 | -  | 1   |
| 11  | 8-HETE                  | 8-hydroxyeicosatetraenoic acid | 319,2>155,1 | -  | 1   |
| 12  | 14-HDoHE                | 14-hydroxy-docosahexaenoic acid | 343,2>205,2 | -  | 1   |
| 13  | 12-HETE                 | 12-hydroxyeicosatetraenoic acid | 319,2>179,1 | -  | 1   |
| 14  | 8-HDoHE                 | 8-hydroxy-docosahexaenoic acid | 343,2>109,1 | -  | 1   |
| 15  | 12-KETE                 | 12-oxo-eicosatetraenoic acid | 317,2>153,1 | -  | 1   |
| 16  | 12,13-EpOME             | 12,13-epoxyoctamonoenoic acid | 295,2>195,2 | -  | 1   |
| 17  | AEA                     | arachidonoyl ethanolamide | 348,2>62,1 | +  | 1   |
| 18  | OEA                     | oleoylethanolamine | 326,2>62,1 | +  | 1   |
| 19  | EPA                     | eicosapentaenoic acid | 301,2>257,2 | -  | 1   |
| 20  | DHA                     | docosahexaenoic acid | 327,2>283,2 | -  | 1   |
| 21  | AA                      | arachidonic acid | 303,2>303,2 | -  | 1   |
| 22  | Sph(17:0) IS            | sphingosine (17:0) IS | 286.3>268.4 | +  | 1   |

**Table S7: Mass transitions for sphingosine-1-phosphate and sphingosine.** The target ion shows the multiple reaction monitoring (MRM) transitions, the ionization polarity (IP) shows the ionization mode of the ESI source and the internal standard (IS) column assigns the number of the internal standard to the compounds with which they were evaluated. The internal standard is marked in bold letters.
|   | Metabolite               | Z Score |   |
|---|--------------------------|---------|---|
| 2 | sphingosine              | 300.4>282.4 | + 1 |
| 3 | sphingosine(17:0) IS     | 286.3>268.4 | + 1 |

**Supplemental results**

**Z score heatmaps**

Z score heatmaps illustrate 13 significantly altered primary metabolites, including 8amino acids, 2amino acid derivates, 2nucleosides and 1catecholamine (Figure S4).
Among the detected 146 phospholipids significant alterations were observed for 8lysophosphatidylcholines (LPC), 37phosphatidylcholines (PC), 9lysophosphatidylethanolamines (LPE), 20phosphatidylethanolamines (PE), 5lysophosphatidylinositols (LPI), 2phosphatidylinositols (PI), 4lysophosphatidylserines (LPS) and 10sphingomyelines (SM) (Supplementary figure5). Nine lipid mediators changed significantly, e.g. eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), oleoyl ethanolamide (OEA), arachidonoyl ethanolamide (AEA) and arachidonic acid (AA) and 4 of its monohydroxides: 11-hydroxyeicosatetraenoic acid (11-HETE), 8-HETE, 19-HETE und 12-HETE (FigureS6).

Log2 fold change heatmaps

Phospholipid analysis revealed 71 phospholipids without significant differences between the groups, Chow and HFD+Pep2.5 (Figure S74). Within these phospholipids PC(34:4), PC(36:7), PE(36:4) and SM(38:3) were significantly elevated in the Chow group compared with the HFD+Veh group as well as significantly elevated in the HFD+Veh group compared with the HFD+Pep2.5 group. Additionally, the group comparison of Chow and HFD+Pep2.5 identified 75 phospholipids with significant differences. Among these phospholipids PC(30:1), PC(30:1), PC(32:0), PE(30:41), SM(34:1) were significantly increased and PE(36:5) were significantly decreased in the groupwise comparisons of HFD+Veh vs. Chow as well as of HFD+Pep2.5 vs. HFD+Veh. Twelve lipid mediators were detected without significant differences and 8 were determined with significant differences when comparing the Chow and HFD+Pep2.5 group. The highlighted (black framed) metabolites in all log2 fold change heatmaps were significantly altered different between Chow and HFD+Veh group as well as between HFD+Veh and HFD+Pep2.5 group. None of the lipid mediators
showed significant differences in groupwise comparisons of HFD+Veh vs. Chow as well as of HFD+Pep2.5 vs. HFD+Veh (Figure S8).

Volcano plots

Volcano plot analysis highlights significantly different analytes with at least twofold changed phospholipids and lipid mediators. The comparison between the Chow group and HFD+Veh group showed a significant decrease or increase of 11 phospholipids in HFD Control group (Supplementary figure 9A), subdivided in 4 reduced classes: PC (6 lipid species), LPE (3), PE (2), PI (1) and 5 elevated classes: LPC (1), PC (3), LPE (1), PE (2) and SM (4). Comparing the Chow and HFD+Pep2.5 group identified 13 significantly decreased and 26 significantly increased phospholipids in HFD+Pep2.5 group (Figure S9B), subdivided in 5 reduced classes: LPC (1), PC (6), LPE (1), PE (4) and PI (1) and 7 elevated classes: LPC (3), PC (9), LPE (1), PE (2), LPS (3), LPS (2) and SM (6). Only 1 PC and 1 PE were significantly decreased and 1 LPC and 2 LPI were significantly increased in the HFD+Pep2.5 group compared with the HFD+Veh group (Figure S9C). The analysis of lipid mediators identified significantly decreased EPA and significantly increased AEA, OEA and 11-HETE in the HFD+Veh group compared with Chow group (Figure S10A) as well as in the HFD+Pep2.5 group compared with Chow group (Figure S10B). The latter group comparison revealed an additional significant elevated lipid mediator: AA. Comparing the HFD+Veh group and HFD+Pep2.5 group, no significant changes for lipid mediators were observed (Figure S10B).

References

[1] Doudney CO, Rinaldi CN. Modification of UV-induced mutation frequency and cell survival of Escherichia coli B/r WP2 trp E65 by treatment before irradiation,” J. Bacteriol. 1984;160(1):233-238.